Company Description
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally.
The company’s lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3Kẟ inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
It also develops Joenja, an oral small molecule PI3Kẟ inhibitor. It has a development collaboration and license agreement with Novartis.
Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.
| Country | Netherlands |
| Founded | 1988 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 407 |
| CEO | Fabrice Chouraqui |
Contact Details
Address: Darwinweg 24 Leiden, 2333 CR Netherlands | |
| Phone | 31 71 524 7400 |
| Website | pharming.com |
Stock Details
| Ticker Symbol | PHAR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 1828316 |
| CUSIP Number | 71716E105 |
| ISIN Number | US71716E1055 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Fabrice Chouraqui Ph.D., Pharm.D. | Chief Executive Officer and Executive Director |
| Kenneth Lynard EMBA | Chief Financial Officer |
| Mireille Sanders M.Sc. | Chief Operations Officer |
| Michael K. Levitan | Vice President of Investor Relations and Corporate Communications |
| Ruud Van Outersterp | Chief Legal and Compliance Officer |
| Ines Bernal | Chief People Officer |
| Dr. Anurag Relan M.D., MPH | Chief Medical Officer |
| Dr. Alexander Breidenbach M.B.A. | Chief Business Officer |
| Leverne Marsh | Chief Commercial Officer |
| Dr. Magnus Hansson | Medical Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 16, 2026 | 6-K | Report of foreign issuer |
| Apr 13, 2026 | 20-F/A | Filing |
| Apr 2, 2026 | 6-K | Report of foreign issuer |
| Apr 2, 2026 | 20-F | Annual and transition report of foreign private issuers |
| Mar 27, 2026 | 6-K | Report of foreign issuer |
| Mar 24, 2026 | 6-K | Report of foreign issuer |
| Mar 12, 2026 | 6-K | Report of foreign issuer |
| Feb 3, 2026 | 6-K | Report of foreign issuer |
| Feb 2, 2026 | 6-K | Report of foreign issuer |
| Jan 8, 2026 | 6-K | Report of foreign issuer |